Granted Patent
B2
US 12,286,413 · App. 17/713,949 · Granted Apr 29, 2025
Compounds and methods for treating cancer
Inventors:
John A. Copland, III (Ponte Vedra Beach, FL); Han W. Tun (Jacksonville, FL); Thomas R. Caulfield (Jacksonville, FL); Christina Von Roemeling (Jacksonville, FL); Laura Ann Marlow (Jacksonville, FL)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.
Claims (32)
1. A compound according to Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is an unsubstituted C 1-6 alkyl or C 1-6 haloalkyl;
X is
Y is selected from the group consisting of:
m is 0 or 1;
n is 0, 1, or 2;
V is NR 4 or O;
R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl; and
Z is an unsubstituted aryl.
2. The compound of claim 1 , wherein the compound according to Formula (I) has the structure of Formula (Ia):
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein R 1 is CF 3 .
4. The compound of claim 1 , wherein m is 0.
5. The compound of claim 1 , wherein Vis NH.
6. The compound of claim 1 , wherein Y is
7. The compound of claim 1 , wherein Y is
8. The compound of claim 1 , wherein m is 1.
9. The compound of claim 1 , wherein Vis O.
10. The compound of claim 9 , wherein Y is
11. The compound of claim 1 , wherein R 2 is H; and R 3 is CH 3 .
12. The compound of claim 11 , wherein Y is
13. The compound of claim 1 , wherein n is 1.
14. The compound of claim 1 , wherein Z is phenyl.
15. The compound of claim 1 , wherein the compound according to Formula (I) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.
17. A method for inhibiting SCD1 in a cancer cell, the method comprising contacting the cancer cell with an effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 .
18. The method of claim 17 , wherein the cancer cell is selected from a kidney cancer cell, a liver cancer cell, a breast cancer cell, a lung cancer cell, a pancreatic cancer cell, a bladder cancer cell, a colon cancer cell, a melanoma cell, a thyroid cancer cell, an ovarian cancer cell, and a prostate cancer cell.
19. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 .
20. The method of claim 19 , wherein the cancer is selected from a kidney cancer, a liver cancer, a breast cancer, a lung cancer, a pancreatic cancer, a bladder cancer, a colon cancer, a melanoma, a thyroid cancer, an ovarian cancer, and a prostate cancer.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 30, 2022
From: COPLAND, JOHN A., III; TUN, HAN W.; CAULFIELD, THOMAS R.; ROEMELING, CHRISTINA VON; MARLOW, LAURA ANN
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 060376/0410 →
Continuity (4)
Continuation
15502301
Provisional Application
62034429
· Aug 7, 2014
References Cited (400)
US 6066730A
· Adams et al.
· 2000
[cited by applicant]
US 6297217B1
· Adams et al.
· 2001
[cited by applicant]
US 6548668B2
· Adams et al.
· 2003
[cited by applicant]
US 6699835B2
· Plamondon et al.
· 2004
[cited by applicant]
US 7014866B2
· Infeld et al.
· 2006
[cited by applicant]
US 7109323B2
· Plamondon et al.
· 2006
[cited by applicant]
US 7531526B2
· Adams et al.
· 2009
[cited by applicant]
US 7547698B2
· Kamboj et al.
· 2009
[cited by applicant]
US 7592343B2
· Kamboj et al.
· 2009
[cited by applicant]
US 7687456B2
· Zhou et al.
· 2010
[cited by applicant]
US 7691852B2
· Shenk et al.
· 2010
[cited by applicant]
US 7767677B2
· Kamboj
· 2010
[cited by examiner]
US 7893066B2
· Koltun et al.
· 2011
[cited by applicant]
US 7944263B2
· Suda
· 2011
[cited by applicant]
US 7960358B2
· Bhanot et al.
· 2011
[cited by applicant]
US 8017761B2
· McSwiggen et al.
· 2011
[cited by applicant]
US 8026360B2
· Kamboj et al.
· 2011
[cited by applicant]
US 8030488B2
· Sviridov et al.
· 2011
[cited by applicant]
US 8071603B2
· Kamboj et al.
· 2011
[cited by applicant]
US 8080545B2
· Shenk et al.
· 2011
[cited by applicant]
US 8080576B2
· Shenk et al.
· 2011
[cited by applicant]
US 8088741B2
· Smyth et al.
· 2012
[cited by applicant]
US 8148378B2
· Gschwend et al.
· 2012
[cited by applicant]
US 8258160B2
· Dales et al.
· 2012
[cited by applicant]
US 8314138B2
· Dales et al.
· 2012
[cited by applicant]
US 8357683B2
· Shenk et al.
· 2013
[cited by applicant]
US 8431571B2
· Shenk et al.
· 2013
[cited by applicant]
US 9233102B2
· Copland, III et al.
· 2016
[cited by applicant]
US 9358250B2
· Ashkenazi
· 2016
[cited by applicant]
US 20030064950A1
· Ntambi et al.
· 2003
[cited by applicant]
US 20050130193A1
· Luxon et al.
· 2005
[cited by applicant]
US 20060079502A1
· Lang
· 2006
[cited by applicant]
US 20060094744A1
· Maryanoff et al.
· 2006
[cited by applicant]
US 20080182851A1
· Thomas et al.
· 2008
[cited by applicant]
US 20100081666A1
· Coughlin et al.
· 2010
[cited by applicant]
US 20100160323A1
· Bischoff et al.
· 2010
[cited by applicant]
US 20100249192A1
· Li et al.
· 2010
[cited by applicant]
US 20110021532A1
· Powell et al.
· 2011
[cited by applicant]
US 20110046134A1
· Bischoff et al.
· 2011
[cited by applicant]
US 20110166152A1
· Leclerc et al.
· 2011
[cited by applicant]
US 20110183958A1
· Powell et al.
· 2011
[cited by applicant]
US 20110213136A1
· Bhanot et al.
· 2011
[cited by applicant]
US 20110301143A1
· Isabel et al.
· 2011
[cited by applicant]
US 20120010186A1
· Lachance et al.
· 2012
[cited by applicant]
US 20120219623A1
· Meinicke
· 2012
[cited by applicant]
US 20160067336A1
· Fand et al.
· 2016
[cited by applicant]
US 20160152986A1
· Copland, III et al.
· 2016
[cited by applicant]
US 20170015654A1
· Imamura et al.
· 2017
[cited by applicant]
US 20190127805A1
· El-Helali et al.
· 2019
[cited by applicant]
US 20230201192A1
· Copland, III et al.
· 2023
[cited by applicant]
US 20230310419A1
· Copland, III et al.
· 2023
[cited by applicant]
EP 2266569
· 2010
[cited by applicant]
EP 2269610
· 2011
[cited by applicant]
WO WO2003006009
· 2003
[cited by applicant]
WO WO2006015621
· 2006
[cited by applicant]
WO WO2006034312
· 2006
[cited by applicant]
WO WO2006034338
· 2006
[cited by applicant]
WO WO2006034440
· 2006
[cited by applicant]
WO WO2006034441
· 2006
[cited by applicant]
WO WO2006101521
· 2006
[cited by applicant]
WO WO2006121250
· 2006
[cited by applicant]
WO WO2006130986
· 2006
[cited by applicant]
WO WO2007005763
· 2007
[cited by applicant]
WO WO2007009236
· 2007
[cited by applicant]
WO WO2007056846
· 2007
[cited by applicant]
WO WO2007071023
· 2007
[cited by applicant]
WO WO2007130075
· 2007
[cited by applicant]
WO WO2007134457
· 2007
[cited by applicant]
WO WO2007143823
· 2007
[cited by applicant]
WO WO2007143824
· 2007
[cited by applicant]
WO WO2008017161
· 2008
[cited by applicant]
WO WO2008020435
· 2008
[cited by applicant]
WO WO2008046226
· 2008
[cited by applicant]
WO WO2008064474
· 2008
[cited by applicant]
WO WO2008074824
· 2008
[cited by applicant]
WO WO2008074832
· 2008
[cited by applicant]
WO WO2008074834
· 2008
[cited by applicant]
WO WO2008089580
· 2008
[cited by applicant]
WO WO2008120759
· 2008
[cited by applicant]
WO WO2009019566
· 2009
[cited by applicant]
WO WO2009020448
· 2009
[cited by applicant]
WO WO2009051581
· 2009
[cited by applicant]
WO WO2009060053
· 2009
[cited by applicant]
WO WO2009060054
· 2009
[cited by applicant]
WO WO2009106991
· 2009
[cited by applicant]
WO WO2009147125
· 2009
[cited by applicant]
WO WO2009154737
· 2009
[cited by applicant]
WO WO2010025553
· 2010
[cited by applicant]
WO WO2010036357
· 2010
[cited by applicant]
WO WO2010079197
· 2010
[cited by applicant]
WO WO2010086411
· 2010
[cited by applicant]
WO WO2010092163
· 2010
[cited by applicant]
WO WO2010094120
· 2010
[cited by applicant]
WO WO2010149640
· 2010
[cited by applicant]
WO WO2011011872
· 2011
[cited by applicant]
WO WO2011030312
· 2011
[cited by applicant]
WO WO2011064352
· 2011
[cited by applicant]
WO WO2011123502
· 2011
[cited by applicant]
WO WO2012151451
· 2012
[cited by applicant]
WO WO2013134546
· 2013
[cited by applicant]
WO WO2014153150
· 2014
[cited by applicant]
WO WO2016022955
· 2016
[cited by applicant]
WO WO2016141299
· 2016
[cited by applicant]
WO WO2016183326
· 2016
[cited by applicant]
WO WO2018160717
· 2018
[cited by applicant]
Abramson, “The lipogenesis pathway as a cancer target,” J. Med. Chem., 54(16):5615-38, Aug. 2011.
[cited by applicant]
Ackerman and Simon, “Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment, ”Trends Cell Biol., 24(8):472-8, Aug. 2014.
[cited by applicant]
Ahn, “An evaluation of phase I cancer clinical trial designs,” Stat. Med., 17(14):1537-49, Jul. 1998.
[cited by applicant]
Angelucci et al., “Stearoyl-CoA desaturase 1 and paracrine diffusible signals have a major role in the promotion of breast cancer cell migration induced by cancer-associated fibroblasts,” Br. J. Cancer. 112(10):1675-86,…
[cited by applicant]
Aparicio et al., “Examining the utility of patient-derived xenograft mouse models,” Nat. Rev. Cancer, 15(5):311-6, Apr. 2015.
[cited by applicant]
Baenke et al., “Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development,” Dis. Model Mech., 6(6):1353-63, Nov. 2013.
[cited by applicant]
Bankaitis, “Unsaturated fatty acid-induced non-canonical autophagy: unusual? or unappreciated?” EMBO J., 34(8);978-80, Apr. 2015.
[cited by applicant]
Bansal et al., “Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma,” J. Surg. Res., 186(1):29-38, Jan. 2014.
[cited by applicant]
Beloribi-Djefaflia et al., “Lipid metabolic reprogramming in cancer cells,” Oncogenesis, 5(1):e189, Jan. 2016.
[cited by applicant]
Ben-David et al., “Selective Elimination of Human Pluripotent Stem Cells by an Oleate Synthesis Inhibitor Discovered in a High-Throughput Screen,” Cell Stem Cell, 12(2):167-79, Feb. 2013.
[cited by applicant]
Berge et al., “Pharmaceutical Salts”, J Pharm Sci., 66(1):1-19, Jan. 1977.
[cited by applicant]
Böhm et al., “Scaffold hopping,” Drug Discov Today: Technologies., 1(3):217-224, 2004.
[cited by applicant]
Brown “Bioisosterism in Medicinal Chemistry”, 2012, Wiley-VCH Verlag GmbH & Co. KGaA, pp. 1-14 (Year: 2012).
[cited by applicant]
Brown and Rudel, “Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery,” Curr. Opin. Lipidol., 21(3):192-7, Jun. 2010.
[cited by applicant]
Cao et al., “Sphereforming cell subpopulations with cancer stem cell properties in human hepatoma cell lines,” BMC Gastroenterol., 11(1):71, Jun. 2011.
[cited by applicant]
Cassidy et al., “Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts,” Cancer Res., 75(15):2963-8, Aug. 2015.
[cited by applicant]
Caulfield et al., “Motion of transfer RNA from the A/T state into the A-site using docking and simulations,” Proteins., 80(11):2489-2500, Nov. 2012.
[cited by applicant]
Chajès et al., “Association between Serum trans-Monounsaturated Fatty Acids and Breast Cancer Risk in the E3N-EPIC Study,” Am. J. Epidemiol., 167(11):1312-20, Apr. 2008.
[cited by applicant]
Chajès et al., “Riboli E. Fatty-acid composition in serum phospholipids and risk of breast cancer: An incident case-control study in Sweden,” Intern. J. Cancer, 83(5):585-90, Nov. 1999.
[cited by applicant]
Chang et al., “KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells,” J. Lipid Res., 46(12):2624-35, Dec. 2005.
[cited by applicant]
Chen et al., “Targeting oncogenic Myc as a strategy for cancer treatment,” Signal transduction and targeted therapy, 3(1):1-7, Feb. 2018.
[cited by applicant]
Chou and Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Adv. Enzyme Regul., 22:27-55, 1984.
[cited by applicant]
Chou et al., “Analysis of combined drug effects: a new look at a very old problem,” Trends in Pharmacological Sciences., 4(11):450-454, 1983.
[cited by applicant]
Chou et al., “Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design,” J. Natl. Cancer Inst., …
[cited by applicant]
Chou, “Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method,” Cancer Res., 70(2):440-6, Jan. 2010.
[cited by applicant]
Chow et al., “The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance,” PLoS One, 8(11):e78675, Nov. 2013.
[cited by applicant]
Conway et al., “Xenome—a tool for classifying reads from xenograft samples,” Bioinformatics, 28(12):i172-8, Jun. 2012.
[cited by applicant]
Cooper et al., “Current status of biomarker discovery in human clear cell renal cell carcinoma,” J. Mol. Biomark Diagn., S2:1-10, 2012.
[cited by applicant]
Copland et al., “Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene., 25(16):2304-2317, Apr. 13, 2006.
[cited by applicant]
Costello B. Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors. [http://www.cancer.gov/about-cancer/treatment/clinicaltrials/search/view?cdrid=761522&version=HealthProfession…
[cited by applicant]
Currie et al., “Cellular Fatty Acid Metabolism and Cancer,” Cell Metabolism, 18(2):153-61, Aug. 2013.
[cited by applicant]
Database accession No. 1390035-79-6, [online] “1-Pi peraz i necarboxami de, 4-benzoyl-N-[2-[[(1,1 dimethylethyl)ami no] carbonyl]phenyl]-,” Aug. 12, 2012, Abstract Only, 1 page.
[cited by applicant]
Demoulin et al., “Platelet-derived Growth Factor Stimulates Membrane Lipid Synthesis Through Activation of Phosphatidylinositol 3-Kinase and Sterol Regulatory Element-binding Proteins,” J. Biol. Chem., 279(34):35392-402…
[cited by applicant]
Dholaria et al., “Emerging therapeutic agents for lung cancer,” Journal of hematology & oncology, 9(1):138, Dec. 2016.
[cited by applicant]
Du et al., “FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth,” Cancer Res., 72(22):5843-55, Nov. 2012.
[cited by applicant]
Du Manoir et al., “Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse,” Mol. Oncol., 8(2):431-43, Mar. 2014.
[cited by applicant]
Einarsdottir et al., “Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions,” Oncotarget, 5(20):9609-18, Oct. 2014.
[cited by applicant]
Extended European Search Report in International Application No. EP15830331.3, dated Mar. 9, 2018, 11 pages.
[cited by applicant]
Falvella et al., “Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats,” Carcinogenesis, 23(11):1933-6, Nov. 2002.
[cited by applicant]
Friesner et al., “Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes,” Journal of medicinal chemistry., 49(21):6177-6196, Oct. 19, 2006.
[cited by applicant]
Fritz et al., “Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice,” Mol. Cancer Therap., 9(6):1740-54, Jun. 2010.
[cited by applicant]
Fu et al., “Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking,” Bioorg Med Chem Lett., 22(22):6848-6853, Nov. 15, 2012.
[cited by applicant]
Fucikovaet al., “Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer,” Front Immunol., 6:402, Aug. 2015.
[cited by applicant]
Gao et al., “High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response,” Nat. Med., 21(11):1318-25, Oct. 2015.
[cited by applicant]
GenBank® Accession No. AF097514.1 (GI No. 4808600), “
[cited by applicant]
GenBank® Accession No. O00767 (GI No. 21431730), “Acyl-CoA desaturase,” Jul. 15, 1998, 11 pages.
[cited by applicant]
Goldberg and Drake, “LAG-3 in Cancer Immunotherapy,” Curr. Top Microbiol. Immunol., 344:269-78, Nov. 2010.
[cited by applicant]
Goodman et al., “Some practical improvements in the continual reassessment method for phase I studies,” Stat. Med., 14(11):1149-61, Jun. 1995.
[cited by applicant]
Gu et al., Autophagyrelated prognostic signature for breast cancer. Mol. Carcinogenesis, 55(3):292-9, Mar. 2016.
[cited by applicant]
Guillou et al, “The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice,” Prog Lipid Res., 49(2):186-199, Apr. 2010.
[cited by applicant]
Guo et al., “EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy,” Sci. Signal., 2(101):ra82, Dec. 2009.
[cited by applicant]
Guo et al., “Therapeutic cancer vaccines: past, present, and future,” Adv. Cancer Res., 119:421-75, Jan. 2013.
[cited by applicant]
Halgren., “Identifying and characterizing binding sites and assessing druggability,” J Chem Inf Model., 49(2):377-389, Feb. 2009.
[cited by applicant]
Halgren., “New method for fast and accurate binding-site identification and analysis,” Chem Biol Dru Des., 69(2):146-148, Feb. 2007.
[cited by applicant]
Hanahan and Weinberg, “Hallmarks of cancer: the next generation,” Cell, 144(5):646-74, Mar. 2011.
[cited by applicant]
Heitjan, “Biology, Models, and the Analysis of Tumor Xenograft Experiments,” Clin. Cancer Res., 17(5):949-52, Jan. 2011.
[cited by applicant]
Herr et al., “Drop-off during ribosome hopping,” J Mol Biol., 311(3):445-452, Aug. 17, 2001.
[cited by applicant]
Hess et al., “Inhibition of StearoylCoA Desaturase Activity Blocks Cell Cycle Progression and Induces Programmed Cell Death in Lung Cancer Cells,” PLoS One, 5(6):e11394, Jun. 2010.
[cited by applicant]
Hetz et al., “Targeting the unfolded protein response in disease,” Nat Rev Drug Discov., 12(9):703-719, Sep. 2013.
[cited by applicant]
Hidalgo et al., “Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research,” Cancer Disc., 4(9):998-1013, Sep. 2014.
[cited by applicant]
Hockla et al., “PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer,” Mol. Cancer Res., 10(12):1555-66, Dec. 2012.
[cited by applicant]
Holland et al., “Wnt signaling in stem and cancer stem cells,” Curr. Opin. Cell Biol., 25(2):254-64., Apr. 2013.
[cited by applicant]
Huang et al., “SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway,” Cancer Lett.., 358(2):180-90, Mar. 2015.
[cited by applicant]
Huard et al., “Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand,” Immunogenetics, 39(3):213-217, Jan. 1994.
[cited by applicant]
Ide et al., “Human breast cancer tissues contain abundant phosphatidylcholine (36: 1) with high stearoyl-CoA desaturase-1 expression,” PLoS One, 8(4):e61204, 2013.
[cited by applicant]
Igal, “Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer,” Carcinogenesis, 31(9):1509-15, Jul. 2010.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2015/044278, Issued Feb. 7, 2017, 7 pages.
[cited by applicant]
International Search Report and the Written Opinion in International Application No. PCT/US2015/044278, mailed Jan. 11, 2016, 14 pages.
[cited by applicant]
Invitation to Pay Additional Fees in International Application No. PCT/US2015/044278, dated Oct. 26, 2015, 2 pages.
[cited by applicant]
Izuishi et al., “Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy,” Cancer Res., 60(21):6201-7, Nov. 2000.
[cited by applicant]
Janssens et al., “Emerging functions of the unfolded protein response in immunity,” Nat. Immunol., 15(10):910-9, Oct. 2014.
[cited by applicant]
Jemal et al., “Global cancer statistics,” CA Cancer J. Clin., 61(2):69-90, Feb. 2011.
[cited by applicant]
Jianli Wang, Scott Saffold, Xuetao Cao, John Krauss, Wei Chen, Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines, The Journal of Immunology, Nov. 15, 1…
[cited by applicant]
Jorgensen et al., “The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin,” J Am Chern Soc., 110(6):1657-1666, Mar. 1, 1…
[cited by applicant]
Kalari et al., “MAP-RSeq: Mayo Analysis Pipeline for RNA sequencing,” BMC Bioinformatics, 15(1):1-11, Jun. 2014.
[cited by applicant]
Kalid et al., “Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors,” J Comput Aided Mol Des., 26(11):1217-1228, Nov. 2012.
[cited by applicant]
Kim et al., “Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities,” Nat Rev Drug Discov., 7(12):1013-1030, Dec. 2008.
[cited by applicant]
Kim et al., “Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation,” Mol. Cells, 31(4):371-7, Apr. 2011.
[cited by applicant]
Koltun et al., “Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors,” Bioorganic Medicinal Chem Lett., 19(7):2048-2052, Apr. 1, 2009.
[cited by applicant]
Koltun et al., “Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors,” Bioorg. Med. Chem. Letters, Apr. 8, 2009, 19(11):3050-3053.
[cited by applicant]
Koltun et al., “Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors,” Bioorg. Med. Chem. Letters, Jun. 13, 2009, 19(15):4070-4074.
[cited by applicant]
Krieger et al., “Assignment of protonation states in proteins and ligands: combining pKa prediction with hydrogen bonding network optimization.,” Methods Mol Biol., 819:405-421, 2012.
[cited by applicant]
Krieger et al., “Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8,” Proteins., 77(Suppl S9):114-122, 2009.
[cited by applicant]
Kuhajda et al., “Fatty acid synthesis: a potential selective target for antineoplastic therapy,” Proc. Natl. Acad. Sci. USA, 91(14):6379-83, 1994.
[cited by applicant]
Kupershmidt et al., Ontology-based meta-analysis of global collections of high-throughput public data, PLoS One., 5(9):e13066, 13 pages Sep. 2010.
[cited by applicant]
Le DT et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. Jun. 25, 2015;372(26):2509-20. (Year: 2015).
[cited by applicant]
Lee et al., “Nutrient-sensing nuclear receptors coordinate autophagy,” Nature, 516(7529):112-5, Nov. 2014.
[cited by applicant]
Lee et al., Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy. Clin. Cancer Res., 21(5):1172-82, Mar. 2…
[cited by applicant]
Leger et al., “Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438),” Bioorg Med Chem Lett., 20(2):499-502, Jan. 15, 2010.
[cited by applicant]
Leung and Kim, “Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress,” Clin. Cancer Res., 19(12):1-3, May 2013.
[cited by applicant]
Li et al., “Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts,” Cell Reports, 4(6):1116-30, Sep. 2013.
[cited by applicant]
Li et al., “SCD1 expression is dispensable for hepatocarcinogenesis induced by AKT and ras oncogenes in mice,” Plos one., 8(9):e75104, Sep. 19, 2013, 12 pages.
[cited by applicant]
Li et al., “Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy,” Oncogene, 30(15):1773-83, 2011.
[cited by applicant]
Li et al., “Thiazole analog as stearoyl-CoA desaturase 1 inhibitor,” Bioorg Med Chem Lett., 19(17):5214-5217, Epub Jul. 9, 2009.
[cited by applicant]
Liang and Sha, “Modeling antitumor activity by using a non-linear mixed-effects model,” Math. Biosci., 189(1):61-73, May 2004.
[cited by applicant]
Liu et al., “Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors,” J Med Chem., 50(13):3086-3100, Jun. 28, 2007.
[cited by applicant]
Liu., “Stearoyl-CoA desaturase inhibitors: update on patented compounds,” Expert Opin Ther Pat., 19(9):1169-1191, 2009.
[cited by applicant]
Llovet et al., “Sorafenib in Advanced Hepatocellular Carcinoma,” N. Engl. J. Med., 359(4):378-90, Jul. 2008.
[cited by applicant]
Loving et al., “Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation,” J computer-aided molecular design., 23(8):541-554, Aug. 2009.
[cited by applicant]
Luyimbazi et al., “Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer,” Mol. Cancer Ther., 9(10):2770-84, Oct. 2010.
[cited by applicant]
Ma et al., “Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation,” Journal of hepatology, 67(5):979-90, Nov. 2017.
[cited by applicant]
Ma, Kin Fai, et al. “Stearoyl-CoA Desaturase (SCD1) regulates liver tumor initiating cells through modulating ER stress,” Cancer Res., 77(13):A4772, 2017. (Abstract).
[cited by applicant]
Marlow et al., “Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target,” J Clin Endocrinol Metab., 95(12):5338-5347…
[cited by applicant]
Marlow et al., “FoxO3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies,” J. Cell Sci., 125(18):4253-63, …
[cited by applicant]
Mason et al., “SCD1 Inhibition Causes Cancer Cell Death by Depleting Mono-Unsaturated Fatty Acids,” PLoS One, 7(3):e33823, Mar. 2012.
[cited by applicant]
Mauvoisin et al., “Decreasing stearoyl-CoA desaturase-1 expression inhibits β-catenin signaling in breast cancer cells,” Cancer Sci., 104(1):36-42, Jan. 2013.
[cited by applicant]
MedicineNet.com (http://www.medterms.com, 2004).
[cited by applicant]
Mellman et al., “Cancer immunotherapy comes of age,” Nature, 480(7378):480-9, Dec. 2011.
[cited by applicant]
Menendez and Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nat. Rev. Cancer, 7(10):763-77, Oct. 2007.
[cited by applicant]
Minville-Walz et al., “Inhibition of Stearoyl-CoA Desaturase 1 Expression Induces CHOP-Dependent Cell Death in Human Cancer Cells,” PLoS One, 5(12):e14363, Dec. 2010.
[cited by applicant]
Mohamadi et al., “Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics,” J Comput Chem., 11(4):440-467, May 1990.
[cited by applicant]
Monsma et al., “Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance,” Pediatr. Blood Cance, 61(9):1570-7, Mar. 2014.
[cited by applicant]
Mounier et al., “Lipogenesis in cancer progression (review),” Int. J. Oncol., 45:485-92, May 2014.
[cited by applicant]
Muir et al., “Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma,” Cancer Res., 73(15):4722-31, Aug. 2013.
[cited by applicant]
Nanda et al., Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase 1b Keynote-012 Study, Journal of Clinical Oncology 34, No. 21 (Jul. 20, 2016) 2460-2467. (Year: 2016).
[cited by applicant]
Naugler et al., “Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production,” Science, 317(5834):121-4, Jul. 2007.
[cited by applicant]
Nelson et al., “Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic,” Toxicol., 266(1-3):6-15, Dec. 2009.
[cited by applicant]
Nile and Hannoush, “Fatty acylation of Wnt proteins,” Nat. Chem. Biol., 12(2):60-9, Jan. 2016.
[cited by applicant]
Niso-Santano et al., “Unsaturated fatty acids induce non-canonical autophagy,” EMBO J., 34(8):1025-41, Jan. 2015.
[cited by applicant]
Noto et al., “Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells,” Cell Death Dis., 4(12):e947, Dec. 2013.
[cited by applicant]
Oballa et al., “Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia,” J Med Chem., 54(14):5082-5096, Epub Ju…
[cited by applicant]
Oesterreich et al., “Using Mice to Treat (WO)men: Mining Genetic Changes in Patient Xenografts to Attack Breast Cancer,” Cell Reports, 4(6):1061-2, Sep. 2013.
[cited by applicant]
Okuda, “Epidemiology of primary liver cancer,” Primary Liver Cancer in Japan, Tobe T (ed)., Chapter 1, pp. 3-15, 1992.
[cited by applicant]
O'Quigley et al., “Continual reassessment method: a practical design for phase 1 clinical trials in cancer,” Biometrics, 46(1):33-48, Mar. 1990.
[cited by applicant]
Pala et al., “Erythrocyte Membrane Fatty Acids and Subsequent Breast Cancer: a Prospective Italian Study,” J. Natl. Cancer Institute, 93(14):1088-95, Jul. 2001.
[cited by applicant]
Pala et al., “Structure-Based Virtual Screening of MT2 Melatonin Receptor: Influence of Template Choice and Structural Refinement,” J Chem Inf Model., 53(4):821-835, Mar. 29, 2013.
[cited by applicant]
Panaretakis et al., “Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death,” EMBO J., 28(5):578-90, Mar. 2009.
[cited by applicant]
Patani and LaVoie, “Bioisosterism: A Rational Approach in Drug Design,” Chem. Rev., 96(8):3147-3176, 1996.
[cited by applicant]
Paton and Ntambi, “Biochemical and physiological function of stearoyl-CoA desaturase,” Am. J. Physiol. Endocrinol. Metab., 297(1):E28-37, Jul. 2009.
[cited by applicant]
Petrek et al., “Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis,” J. Clin. Oncol., 15(4):1377-84, Apr. 1997.
[cited by applicant]
Petrova et al., “TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding,” Clinical Cancer Research, 23(4):1068-79, Feb. 2017.
[cited by applicant]
Porstmann et al., “PKB//Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP,” Oncogene, 24(43):6465-81, Jun. 2005.
[cited by applicant]
Porstmann et al., “SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth,” Cell Metab., 8(3):224-36, Sep. 2008.
[cited by applicant]
Powell et al., “2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors,” Bioorg Med Chem Lett., 20(22):6366-6369, Nov. 15, 2010.
[cited by applicant]
Powers, “Cell Growth Control: mTOR Takes on Fat,” Mol. Cell, 31(6):775-6, Sep. 2008.
[cited by applicant]
Pubchem, Substance Record for SID 144964572, AKOS008653309, Available Oct. 18, 2012, retrieved on Oct. 30, 2015, Retrieved from the Internet, URL: https://pubchem.ncbi.nlm.nih.gov/substance/144964572/version/1>, 6 pages.
[cited by applicant]
Rathert et al., “Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.,” Nature, 525(7570):543-7, Sep. 2015.
[cited by applicant]
Reya and Clevers, “Wnt signalling in stem cells and cancer,” Nature, 434(7035):843-50, Apr. 2005.
[cited by applicant]
Rodvold et al., “Immune modulation by ER stress and inflammation in the tumor microenvironment,” Cancer Letters, 380(1):227-36, Sep. 2016.
[cited by applicant]
Roemeling et al., “Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target,” J. Clin. Endocrinol. Metab., 100(5): E697-E709, May 2015.
[cited by applicant]
Roemeling et al., “Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma”, Clin Canc Res., 19(9):2368-2380, Apr. 30, 2013.
[cited by applicant]
Roongta et al., “Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy,” Mol Cancer Res., 9(11):1551-1561, Nov. 2011.
[cited by applicant]
Rosenberg, “Raising the bar: the curative potential of human cancer immunotherapy,” Sci. Transl. Med., 4(127):127ps8, Mar. 2012.
[cited by applicant]
Ruddigkeit et al., “Visualization and virtual screening of the chemical universe database GDB-17,” J Chem Inf Model., 53(1):56-65, Dec. 23, 2012.
[cited by applicant]
Rysman et al., “De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation,” Cancer Res., 70(20):8117-26, Oct. 2010.
[cited by applicant]
Sampath and Ntambi, “The role of stearoyl-CoA desaturase in obesity, insulin resistance, and inflammation,” Ann. N.Y Acad. Sci., 1243(1):47-53, Dec. 2011.
[cited by applicant]
Sandor et al., “Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes,” J Chem Inf Model., 50(6):1165-1172, Jun. 2010.
[cited by applicant]
Santos and Schulze, “Lipid metabolism in cancer,” FEBS J., 279(15):2610-23, Aug. 2012.
[cited by applicant]
Sastry et al., “Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking,” J Chem Inf Model., 53(7):1531-1542, 2013.
[cited by applicant]
Sastry et al., “Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring,” J Chem Inf Model., 51(10):2455-2466, Sep. 15, 2011.
[cited by applicant]
Scaglia et al., “Inhibition of StearoylCoA Desaturase-1 Inactivates Acetyl-CoA Carboxylase and Impairs Proliferation in Cancer Cells: Role of AMPK,” PLoS One, 4(8):e6812, Aug. 2009.
[cited by applicant]
Schlaepfer et al., “Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel,” Mol. Cell. Endocrin., 363(1-2):111-21, Aug. 2012.
[cited by applicant]
Schmittgen et al., “Analyzing real-time PCR data by the comparative C(T) method,” Nat Protoc., 3(6): 1101-1108, 2008.
[cited by applicant]
Seok et al., “Transcriptional regulation of autophagy by an FXR-CREB axis,” Nature, 516(7529):108-11, Dec. 2014.
[cited by applicant]
Siolas and Hannon, “Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models,” Cancer Res., 73(17):5315-9, Sep. 2013.
[cited by applicant]
Song et al., “Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells,” Autophagy, 5(8):1131-44, Nov. 2009.
[cited by applicant]
Sorafenib Package Insert and Prescribing Information. 2010.
[cited by applicant]
Sperandio et al., “MED-SuMoLig: A New Ligand-Based Screening Tool for Efficient Scaffold Hopping,” J Chem Inf Model., 47(3):1097-1110, 2007.
[cited by applicant]
Sun, “Classification of scaffold-hopping approaches,” Drug discovery today., 17(7-8):310-324, Apr. 2012.
[cited by applicant]
Tun et al., “Pathway signature of clear cell renal cell carcinoma,” PLoS One, 5:e10696, May 2010.
[cited by applicant]
Tusher et al., “Significance analysis of microarrays applied to the ionizing radiation response,” Proc. Natl. Acad. Sci. USA, 98(9):5116-21, Apr. 2001.
[cited by applicant]
Uto et al., “Discovery of novel SCD1 inhibitors: 5-Alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4′-piperidine] analogs,” Eur J Med Chem., 46(5):1892-1896, May 2011.
[cited by applicant]
Uto et al., “Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide,” Bioorg. Med. Chem. Letters, Jun. 2, 2009, …
[cited by applicant]
Uto et al., “Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation,” Bio…
[cited by applicant]
Uto et al., “Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-y1}-3,4-dihydrospiro[chromene-2,4′-piperidine] analogs,” Eur J Med Chem…
[cited by applicant]
Vivoli et al., “Inhibition of Prohormone Convertases PC1/3 and PC2 by 2,5-Dideoxystreptamine Derivatives,” Mol Pharmacol., 81(3):440-454, Mar. 2012.
[cited by applicant]
Von Roemeling and Copland, “Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma,” Expert Opin. Ther. Targets, 20(2):159-66, Sep. 2015.
[cited by applicant]
Von Roemeling et al, “Aberrant Lipid Metabolism in Anaplastic Thyroid Carcinoma Reveals Stearoyl CoA Desaturase 1 as a Novel Therapeutic Target,” J. Clin. Endocrinol. Metab., 100(5):E697-709, May 2015.
[cited by applicant]
Von Roemeling et al., “Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy,” Oncotarget, Oct. 6, 2017, 9(1):3-20.
[cited by applicant]
Von Roemeling et al., “Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration,” Oncotarget, 5(14):5320-34, Jun. 2014.
[cited by applicant]
Von Roemeling et al., “Neuronal Pentraxin 2 is a regulator of clear cell renal cell carcinoma malignancy through activation of the AMPA-selective glutamate receptor-4,” Cancer Res., 75(17):4796-810, Jun. 2014.
[cited by applicant]
Von Roemeling et al., “Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma,” Clin. Cancer Res., 19(9):2368-80, May 2013.
[cited by applicant]
Voss et al., “Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1),” Eur. J. Pharmacol.,. 707(1-3):140-6, May 2013.
[cited by applicant]
Walter., “The unfolded protein response: from stress pathway to homeostatic regulation,” Science., 334(6059):1081-1086, Nov. 25, 2011.
[cited by applicant]
Wang and Shen et al., “Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response,” J Biol Chem., 275(35):27013-27020, Sep. 1, 2000.
[cited by applicant]
Watts et al., “A Conformational Search Method for Efficient Generation of Bioactive Conformers,” J Chem Inf Model., 50(4):534-546, Apr. 26, 2010.
[cited by applicant]
Whittle et al., “Patient-derived xenograft models of breast cancer and their predictive power,” Breast Cancer Res., 17(1):17, Feb. 2015.
[cited by applicant]
Woo et al., “Innate immune recognition of cancer,” Annual review of immunology, 33:445-74, Mar. 2015.
[cited by applicant]
Wu and Irizarry, “Preprocessing of oligonucleotide array data,” Nat. Biotechnol., 22(6):656-8, Jun. 2004.
[cited by applicant]
Wurz et al., “Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential,” Ther. Adv. Med. Oncology, 8(1):4-31, Jan. 2016.
[cited by applicant]
Xin et al., “Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors,” Bioorg Med Chem Lett., 18(15):4298-4302, Aug. 1, 2008.
[cited by applicant]
Xu et al., “Endoplasmic reticulum stress: cell life and death decisions,” J Clin Invest., 115(10):2656-2664, Oct. 2005.
[cited by applicant]
Yahagi et al., “Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma,” European Journal of Cancer, 41(9):1316-22, Jun. 2005.
[cited by applicant]
Zhang and Du, “Dysregulated lipid metabolism in cancer,” World journal of biological chemistry, 3(8):167, Aug. 2012.
[cited by applicant]
Zhang et al., “Positive feedback loop and synergistic effects on promoting tumorgenesis between HIF-2α and SCD1 in clear cell renal cell carcinoma,” Cancer Sci., 104:416-22, Apr. 2013.
[cited by applicant]
Zhang et al., “Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer,” Mol. Cell. Proteomics, 4(11):1686-96, Nov. 2005.
[cited by applicant]
Zhang et al., “Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways,” Mol. Med. Rep., 9(1):83-90, Jan. 2014.
[cited by applicant]
Zhao et al., “Bayesian Hierarchical Changepoint Methods in Modeling the Tumor Growth Profiles in Xenograft Experiments,” Clin. Cancer Res., 17(5):1057-64, Mar. 2011.
[cited by applicant]
Zhou., “Improving threading algorithms for remote homology modeling by combining fragment and template comparisons,” Proteins., 78(9):2041-2048, Jul. 2010.
[cited by applicant]
Zhou., “Protein structure prediction by Pro-Sp3-TASSER,” Biophys J., 96(6):2119-2127, Mar. 2009.
[cited by applicant]
Zhou., “Template-based protein structure modeling using TASSER(VMT),” Proteins., 80(22);352-361, Feb. 2012.
[cited by applicant]
Zureik et al., “Fatty acid proportions in cholesterol esters and risk of premature death from cancer in middle aged French men,” BMJ. 311(7015):1251-4, Aug. 1995.
[cited by applicant]
U.S. Appl. No. 16/368,477, filed Mar. 28, 2019, John A. Copland III, Issued as U.S. Pat. No. 11,243,207.
[cited by applicant]
U.S. Appl. No. 16/489,133, filed Aug. 27, 2019, Christina Von Roemeling, Published as US. Publication No. 2020/0061055.
[cited by applicant]
Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. Feb. 13, 2017;1(6):e000122. doi: 10.1136/esmoopen-2016-00…
[cited by applicant]
Akkaya et al., “Second signals rescue B cells from activation-induced mitochondrial dysfunction and death,” Nat. Immunology, Jul. 9, 2018 19(8):871-884.
[cited by applicant]
Aljohani et al., “Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism,” Trends Endocrinol. Metabolism, Dec. 2017, 28(12):831-842.
[cited by applicant]
Alwarawrah et al., “Changes in Nutritional Status Impact Immune Cell Metabolism and Function,” Front. Immunology, May 16, 2018, 9:1055, 14 pages.
[cited by applicant]
Balmer et al., “Memory CD8(+) T Cells Require Increased Concentrations of Acetate Induced by Stress for Optimal Function,” Immunity, Jun. 21, 2016, 44(6):1312-1324.
[cited by applicant]
BioVision [online], “SCD1 Inhibitor,” archived Sep. 24, 2013. Retrieved from the Internet: <URL: http://www.biovision.com/scd1-inhibitor-3983.html>, 1 page.
[cited by applicant]
Boothby et al., “Metabolic Regulation of the Immune Humoral Response,” Immunity, May 16, 2017, 46(5):743-755.
[cited by applicant]
Caro-Maldonado et al., “Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells,” J. Immunology, Apr. 15, 2014, 192(8):3626-3636.
[cited by applicant]
Carter et al., “The global burden of SLE: prevalence, health disparities and socioeconomic impact,” Nat. Rev. Rheumatology, Oct. 2016, 12(10):605-620.
[cited by applicant]
Chan, “Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer,” Br J Cancer., 91(8):1420-1424, Oct. 18, 2004.
[cited by applicant]
Chiba et al., “Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1,” Nat. Immunol., Sep. 2012, 13(9):832-842.
[cited by applicant]
Cho et al., “Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family,” Proc. Natl. Acad. Sci. USA, Sep. 20, 2011, 108(38):15972-15977.
[cited by applicant]
ClinicalTrials.gov [online], “A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2),” NCT 00846391, Feb. 17, 2009 [retrived on Aug…
[cited by applicant]
ClinicalTrials.gov [online], “A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(Completed),” NCT 00790556, Nov. 7, 2008 [retrieved on Aug. 31, 2015]. Retrieved from…
[cited by applicant]
ClinicalTrials.gov [online], “Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012),” NCT 00972322, Sep. 3, 2009 [retrieved on Aug. 31, 2015]. Retrieved from the Internet: <…
[cited by applicant]
Cohen et al., “Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss,” Science, 297(5579):240-243, Jul. 12, 2002.
[cited by applicant]
Cooper et al., “Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers,” Mol Cancer Ther., 11(10):2105-2115, Epub Jul. 23, 2012.
[cited by applicant]
Crouch et al., “Frontline science: a reduction in DHA-derived mediators in male obesity contributes toward defects in select B cell subsets and circulating antibody,” J. Leukoc. Biology, Aug. 2019, 106(2):241-257.
[cited by applicant]
De Boer et al., “Transgenic mice with hematopoietic and lymphoid specific expression of Cre,” Eur. J. Immunology, Feb. 2003, 33(2):314-325.
[cited by applicant]
DiMauro et al., “Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2,” Bioorg Med Chem Lett., 18(15):4267-4274, Epub Jul. 13, 2008.
[cited by applicant]
Dobrzyn et al., “Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart,” Am J Physiol Endocrinol Metab., 294(2):E357-E364, Epub Nov. 27, 2007.
[cited by applicant]
Dobrzyn et al., “Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver,” Proc. Natl. Acad. Sci. USA, Apr. 27, 2004, 101(17):6409-6414.
[cited by applicant]
Dondeti et al., “Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets,” Cancer Res., 72(1):112-121, Epub Nov. 17, 2011.
[cited by applicant]
Dufort et al., “Cutting edge: IL-4-mediated protection of primary B lymphocytes from apoptosis via Stat6-dependent regulation of glycolytic metabolism,” J. Immunology, Oct. 15, 2007, 179(8):4953-4957.
[cited by applicant]
Dufort et al., “Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation,” J. Biol. Chemistry, Mar. 7, 2014, 289(10):7011-7024.
[cited by applicant]
Economopoulou et al., “The promise of immunotherapy in head and neck squamous cell carcinoma,” Annals of Oncology, Jul. 2016, 27:1675-1685.
[cited by applicant]
Fagarasan et al., “Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis,” Annu. Rev. Immunology, Mar. 1, 2010, 28:243-273.
[cited by applicant]
Falvella et al., “Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats,” Carcinogenesis, Nov. 2002, 23(11):1933-1936.
[cited by applicant]
Fritsche, “Fatty acids as modulators of the immune response,” Annu. Rev. Nutrition, Aug. 21, 2006, 26:45-73.
[cited by applicant]
Fritsche, “The science of fatty acids and inflammation,” Adv. Nutrition, May 15, 2015, 6(3):293S-301S.
[cited by applicant]
Fritz et al., “Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice,” Mol Cancer Ther., 9(6):1740-1754, Epub Jun. 8…
[cited by applicant]
Gally et al., “FABP5 deficiency enhances susceptibility to H1N1 influenza A virus-induced lung inflammation,” Am. J. Physiol. Lung Cell Mol. Physiology, Jul. 1, 2013, 305(1):L64-72.
[cited by applicant]
GenBank Accession No. AB032261.1, “
[cited by applicant]
GenBank Accession No. AB208982.1, “
[cited by applicant]
GenBank Accession No. NC_000010.11, “
[cited by applicant]
GenBank Accession No. NM_005063.5, “
[cited by applicant]
GenBank Accession No. XM_001723785.1, “Predicted:
[cited by applicant]
GenBank Accession No. XM_001725202.1, “Predicted:
[cited by applicant]
GenBank Accession No. O00767.2, “Acyl-CoA desaturase,” dated Feb. 8, 2011, 6 pages.
[cited by applicant]
Gurzell et al., “DHA-enriched fish oil targets B cell lipid microdomains and enhances ex vivo and in vivo B cell function,” J. Leukoc. Biology, Apr. 2013, 93(4):463-470.
[cited by applicant]
Hertzel et al., “Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice,” Am. J. Physiol. Endocrinol. Metabolism, May 2006, 290(5):E814-823.
[cited by applicant]
Hobeika et al., “Testing gene function early in the B cell lineage in mb1-cre mice,” Proc. Natl. Acad. Sci. USA, Sep. 12, 2006, 103(37):13789-13794.
[cited by applicant]
Hotamisligil et al., “Metabolic functions of FABPs—mechanisms and therapeutic implications,” Nat. Rev. Endocrinology, Oct. 2015, 11(10):592-605.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/020257 dated Sep. 12, 2019, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/037625, mailed on Dec. 29, 2022, 7 pages.
[cited by applicant]
International Search Report & Written Opinion in International Application No. PCT/US2018/020257 dated May 14, 2018, 16 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/037625, mailed on Oct. 12, 2021, 9 pages.
[cited by applicant]
Issandou et al., “Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models,” Eur J Pharmacol., 618(1-3):28-36, Epub Jul. 17, 2009.
[cited by applicant]
Iwata et al., “Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism,” J. Immunology, Sep. 15, 2016, 197(6):2250-2260.
[cited by applicant]
Jones et al., “mTOR has distinct functions in generating versus sustaining humoral immunity,” J. Clin. Investigation, Nov. 1, 2016, 126(11):4250-4261.
[cited by applicant]
Kaestner et al., “Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase,” J. Biol. Chemistry, Sep. 5, 1989, 264(25):14755-14761.
[cited by applicant]
Kedia-Mehta et al., “Competition for nutrients and its role in controlling immune responses,” Nat. Communications, May 9, 2019, 10(1):2123.
[cited by applicant]
Kim et al., “Identification of genes differentially expressed in the renal cell carcinoma by microarray,” The Korean Society for Laboratory Medicine, [author manuscript], 2009, 1 page.
[cited by applicant]
Kim et al., “mTOR: a pharmacologic target for autophagy regulation,” J. Clin. Investigation, Jan. 2015, 125(1):25-32.
[cited by applicant]
Kim et al., “TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions,” Genome Biology, Apr. 25, 2013, 14(4):R36, 13 pages.
[cited by applicant]
Kosaraju et al., “B Cell Activity Is Impaired in Human and Mouse Obesity and Is Responsive to an Essential Fatty Acid upon Murine Influenza Infection,” J. Immunology, Jun. 15, 2017, 198(12):4738-4752.
[cited by applicant]
Koutsari et al., “Measuring plasma fatty acid oxidation with intravenous bolus injection of 3H- and 14C-fatty acid,” J. Lipid Research, Jan. 2013, 54(1):254-264.
[cited by applicant]
Kunisawa et al., “Regulation of intestinal IgA responses by dietary palmitic acid and its metabolism,” J. Immunology, Aug. 15, 2014, 193(4):1666-1671.
[cited by applicant]
Kurmi et al., “Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity,” Cell Reports, Feb. 6, 2018, 22(6):1365-1373.
[cited by applicant]
Le et al., “Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells,” Cell Metabolism, Jan. 4, 2012, 15(1):110-121.
[cited by applicant]
Lee et al., “Requirement for Rictor in homeostasis and function of mature B lymphoid cells,” Blood, Oct. 3, 2013, 122(14):2369-2379.
[cited by applicant]
Li et al., “Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues,” Int J Cancer., 57(3):348-352, May 1994.
[cited by applicant]
Liou et al., “Microarray gene expression profiling and analysis in renal cell carcinoma,” BMC Urol., 4:9, 11 pages, Jun. 22, 2004.
[cited by applicant]
Ma et al., “Serine Is an Essential Metabolite for Effector T Cell Expansion,” Cell Metabolism, Feb. 7, 2017, 25(2):345-357.
[cited by applicant]
Marlow et al., “cMyc expression and glycolysis addiction are necessary for SCD1 inhibitor response,” Poster presented at the proceedings of the AACR Annual Meeting, Jun. 2020, 1 page.
[cited by applicant]
McAnuff et al., “Potency of siRNA versus shRNA mediated knockdown in vivo,” J Pharm Sci., 96(11):2922-2930, Nov. 2007.
[cited by applicant]
Miyazaki et al., “A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis,” J. Lipid Research…
[cited by applicant]
Miyazaki et al., “Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis,” Cell Metab., Dec. 2007, 6(6):484-496.
[cited by applicant]
Miyazaki et al., “Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid,” J. Nutrition, Sep. 2001, 131(9):2260-2268.
[cited by applicant]
Mizushima et al., “The role of Atg proteins in autophagosome formation,” Annu. Rev. Cell Dev. Biology, Nov. 2011, 27:107-132.
[cited by applicant]
Moore et al., “Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma,” Int J Cancer., 114(4):563-571, Apr. 20, 2005.
[cited by applicant]
Morgan-Lappe et al., “Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen,” Cancer Res…
[cited by applicant]
Ntambi et al., “Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity,” Proc. Natl. Acad. Sci. USA, Aug. 20, 2002, 99(17):11482-11486.
[cited by applicant]
Ogasawara et al., “Stearoyl-CoA desaturase 1 activity is required for autophagosome formation,” J. Biol. Chemistry, Aug. 22, 2014, 289(34):23938-23950.
[cited by applicant]
O'Sullivan et al., “Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development,” Immunity, Jul. 17, 2014, 41(1):75-88.
[cited by applicant]
Persson et al., “Rapid measurement of plasma free fatty acid concentration and isotopic enrichment using LC/MS,” J. Lipid Research, Sep. 2010, 51(9):2761-2765.
[cited by applicant]
Pisanu et al., “Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma,” J. Exp Clin. Cancer Res., Dec. 2018, 37(1):318.
[cited by applicant]
PR Newswire [online], “Xenon and Novartis Sign Drug Development Deal for Obesity and Metabolic Disorders,” Sep. 20, 2004 [retrieved on Apr. 23, 2015]. Retrieved from the Internet: <URL: http://www.prnewswire.com/news-re…
[cited by applicant]
PubChem [online], “2-(4-(2-(Trifluoromethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxamide,” PubChem CID 11973722, created Jan. 3, 2007, modified Apr. 19, 2015 [retrieved on Apr. 23, 2015]. Retrieved from the Internet: <…
[cited by applicant]
Ramon et al., “Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells,” J. Immunology, Jul. 15, 2012, 189(2):1036-1042.
[cited by applicant]
Ramon et al., “The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?” J. Immunol., Dec. 2014, 193(12):6031-6040.
[cited by applicant]
Ramtohul et al., “Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors,” Bioorg Med Chem Lett., 21(19):5692-5696, Epub Aug. 12, 2011.
[cited by applicant]
Rangel-Moreno et al., “B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms,” J. Immunology, Jan. 1, 2008, 180(1):454-463.
[cited by applicant]
Rathi et al, “Piperazine derivatives for therapeutic use: a patent review (2010-present),” Expert Opin. Ther. Pat., Jul. 2016, 26(7):777-797.
[cited by applicant]
Raybuck et al., “B Cell-Intrinsic mTORC1 Promotes Germinal Center-Defining Transcription Factor Gene Expression, Somatic Hypermutation, and Memory B Cell Generation in Humoral Immunity,” J. Immunology, Apr. 15, 2018, 20…
[cited by applicant]
Rickert et al., “B lymphocyte-specific, Cre-mediated mutagenesis in mice,” Nucleic Acids Research, Mar. 1, 1997, 25(6):1317-1318.
[cited by applicant]